Mark Goldsmith, Revolution Medicines CEO (Mark Kauzlarich/Bloomberg via Getty Images)
December 8, 2022 07:16 AM EST
Deals

Sanofi walks away from $500M deal, leav­ing Rev­o­lu­tion alone in push­ing SHP2/KRAS com­bo

Amber Tong

In the four years since Sanofi teamed up with Rev­o­lu­tion Med­i­cines around its SHP2 in­hibitor — fronting a $500 mil­lion deal with $50 mil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times